Literature DB >> 18559586

Tissue-based research in kidney cancer: current challenges and future directions.

Sabina Signoretti1, Gennady Bratslavsky, Frederick M Waldman, Victor E Reuter, John Haaga, Maria Merino, George V Thomas, Michael R Pins, Towia Libermann, John Gillespie, Joseph E Tomaszewski, Carolyn C Compton, Andrew Hruszkewycz, W Marston Linehan, Michael B Atkins.   

Abstract

The past several years have seen unprecedented advances in the application of various therapeutic strategies for the treatment of patients with renal cancer. The availability of active immunotherapy, antiangiogenic therapy, and targeted therapy for this disease has brought front and center issues related to choosing the appropriate treatment for particular patient populations. It is increasingly evident that the most promising treatment selection strategies will incorporate identifying specific features of the tumor itself. To facilitate this move toward personalized medicine, it is critically important to establish some standard principles for renal cancer tissue collection, preparation, and analysis for translational research studies. In this article, we identify and discuss some critical issues related to tissue-based kidney cancer research. We focus on five major areas as follows: (a) surgical and image-guided techniques for tissue collection; (b) quality control of specimen collection, processing, storage, and review; (c) issues related to analysis of paraffin embedded tissues; (d) genomic studies; and (e) assessment of reproducibility of assays across institutions. In addition, some practical implementation strategies are proposed. Although many of the topics discussed are specific for renal cancer, several are also relevant to tissue based biomarker investigations in a broad array of malignancies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18559586      PMCID: PMC2586673          DOI: 10.1158/1078-0432.CCR-07-4733

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Long-term preservation of antigenicity on tissue microarrays.

Authors:  Kyle A DiVito; Lori A Charette; David L Rimm; Robert L Camp
Journal:  Lab Invest       Date:  2004-08       Impact factor: 5.662

2.  Gene signatures of progression and metastasis in renal cell cancer.

Authors:  Jon Jones; Hasan Otu; Dimitrios Spentzos; Shakirahmed Kolia; Mehmet Inan; Wolf D Beecken; Christian Fellbaum; Xuesong Gu; Marie Joseph; Allan J Pantuck; Dietger Jonas; Towia A Libermann
Journal:  Clin Cancer Res       Date:  2005-08-15       Impact factor: 12.531

Review 3.  Renal-cell carcinoma.

Authors:  Herbert T Cohen; Francis J McGovern
Journal:  N Engl J Med       Date:  2005-12-08       Impact factor: 91.245

4.  Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer.

Authors:  George V Thomas; Chris Tran; Ingo K Mellinghoff; Derek S Welsbie; Emily Chan; Barbara Fueger; Johannes Czernin; Charles L Sawyers
Journal:  Nat Med       Date:  2005-12-11       Impact factor: 53.440

5.  Percutaneous biopsy of renal masses: sensitivity and negative predictive value stratified by clinical setting and size of masses.

Authors:  Frank J Rybicki; Kirstin M Shu; Edmund S Cibas; Julia R Fielding; Eric vanSonnenberg; Stuart G Silverman
Journal:  AJR Am J Roentgenol       Date:  2003-05       Impact factor: 3.959

6.  Fine-needle percutaneous biopsy of renal masses with helical CT guidance.

Authors:  E Lechevallier; M André; D Barriol; L Daniel; C Eghazarian; M De Fromont; D Rossi; C Coulange
Journal:  Radiology       Date:  2000-08       Impact factor: 11.105

Review 7.  Technology insight: Identification of biomarkers with tissue microarray technology.

Authors:  Jena M Giltnane; David L Rimm
Journal:  Nat Clin Pract Oncol       Date:  2004-12

8.  Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.

Authors:  Michael Atkins; Meredith Regan; David McDermott; James Mier; Eric Stanbridge; Amanda Youmans; Philip Febbo; Melissa Upton; Mirna Lechpammer; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2005-05-15       Impact factor: 12.531

Review 9.  Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.

Authors:  Robert J Motzer; Jennifer Bacik; Madhu Mazumdar
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

10.  Prognostic significance of morphologic parameters in renal cell carcinoma.

Authors:  S A Fuhrman; L C Lasky; C Limas
Journal:  Am J Surg Pathol       Date:  1982-10       Impact factor: 6.394

View more
  10 in total

1.  Bridging the gap: moving predictive and prognostic assays from research to clinical use.

Authors:  P Michael Williams; Tracy G Lively; J Milburn Jessup; Barbara A Conley
Journal:  Clin Cancer Res       Date:  2012-03-15       Impact factor: 12.531

2.  The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.

Authors:  Toni K Choueiri; André P Fay; Robert Gagnon; Ying Lin; Brittany Bahamon; Victoria Brown; Jonathan E Rosenberg; Thomas E Hutson; Katherine L Baker-Neblett; Christopher Carpenter; Yuan Liu; Lini Pandite; Sabina Signoretti
Journal:  Clin Cancer Res       Date:  2013-07-23       Impact factor: 12.531

3.  PD-L1 Expression and Clinical Outcomes to Cabozantinib, Everolimus, and Sunitinib in Patients with Metastatic Renal Cell Carcinoma: Analysis of the Randomized Clinical Trials METEOR and CABOSUN.

Authors:  Toni K Choueiri; Sabina Signoretti; Abdallah Flaifel; Wanling Xie; David A Braun; Miriam Ficial; Ziad Bakouny; Amin H Nassar; Rebecca B Jennings; Bernard Escudier; Daniel J George; Robert J Motzer; Michael J Morris; Thomas Powles; Evelyn Wang; Ying Huang; Gordon J Freeman
Journal:  Clin Cancer Res       Date:  2019-08-01       Impact factor: 12.531

Review 4.  Turning laboratory findings into therapy: a marathon goal that has to be reached.

Authors:  Beatrix Kotlan; David F Stroncek; Francesco M Marincola
Journal:  Pol Arch Med Wewn       Date:  2009-09

Review 5.  Tissue biomarkers in renal cell carcinoma: issues and solutions.

Authors:  Arianna Di Napoli; Sabina Signoretti
Journal:  Cancer       Date:  2009-05-15       Impact factor: 6.860

6.  Patterns of gene expression and copy-number alterations in von-hippel lindau disease-associated and sporadic clear cell carcinoma of the kidney.

Authors:  Rameen Beroukhim; Jean-Philippe Brunet; Arianna Di Napoli; Kirsten D Mertz; Apryle Seeley; Maira M Pires; David Linhart; Robert A Worrell; Holger Moch; Mark A Rubin; William R Sellers; Matthew Meyerson; W Marston Linehan; William G Kaelin; Sabina Signoretti
Journal:  Cancer Res       Date:  2009-06-01       Impact factor: 12.701

Review 7.  Positron emission tomography in renal cell carcinoma: an imaging biomarker in development.

Authors:  Amir H Khandani; W Kimryn Rathmell
Journal:  Semin Nucl Med       Date:  2012-07       Impact factor: 4.802

8.  Von Hippel-Lindau (VHL) inactivation in sporadic clear cell renal cancer: associations with germline VHL polymorphisms and etiologic risk factors.

Authors:  Lee E Moore; Michael L Nickerson; Paul Brennan; Jorge R Toro; Erich Jaeger; Jessica Rinsky; Summer S Han; David Zaridze; Vsevolod Matveev; Vladimir Janout; Hellena Kollarova; Vladimir Bencko; Marie Navratilova; Neonilia Szeszenia-Dabrowska; Dana Mates; Laura S Schmidt; Petra Lenz; Sara Karami; W Marston Linehan; Maria Merino; Stephen Chanock; Paolo Boffetta; Wong-Ho Chow; Frederic M Waldman; Nathaniel Rothman
Journal:  PLoS Genet       Date:  2011-10-13       Impact factor: 5.917

9.  Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity.

Authors:  Rosalie Fisher; James Larkin; Charles Swanton
Journal:  EPMA J       Date:  2011-12-22       Impact factor: 6.543

10.  The surgical specimen is the personalized part of personalized cancer medicine.

Authors:  Carolyn C Compton
Journal:  Ann Surg Oncol       Date:  2009-05-27       Impact factor: 5.344

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.